The latest price target for Neurogene (NASDAQ:NGNE) was reported by HC Wainwright & Co. on November 25, 2024. The analyst firm set a price target for $55.00 expecting NGNE to rise to within 12 months (a possible 146.14% upside). 23 analyst firms have reported ratings in the last year.

The latest analyst rating for Neurogene (NASDAQ:NGNE) was provided by HC Wainwright & Co., and Neurogene reiterated their buy rating.

There is no last upgrade for Neurogene

There is no last downgrade for Neurogene.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Neurogene, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Neurogene was filed on November 25, 2024 so you should expect the next rating to be made available sometime around November 25, 2025.

While ratings are subjective and will change, the latest Neurogene (NGNE) rating was a reiterated with a price target of $55.00 to $55.00. The current price Neurogene (NGNE) is trading at is $22.35, which is out of the analyst’s predicted range.